



[The Digital Examiner](#)
www.prostaaid.org

“Issue #297” September 2024

***LIGHT UP IN BLUE
FOR PROSTATE CANCER
AWARENESS MONTH***



CALGARY



*Click on the button below to see
what's lighting up near you!*

[Light Up Locations](#)

Warriors Lunch Meeting

PROSTADID Calgary has booked the boardroom at CKE Community Centre 1015 – 73 Avenue SW for Tuesday September 3rd from 11:30am to 1:00pm.

PROSTADID will supply the pizza for those able to attend.

[Please RSVP to program.director@prostaidd.org](mailto:program.director@prostaidd.org).

We're look forward to seeing you all again and finding out how you are doing.

All of our monthly General meetings are in person or via Zoom

Location for in person is:

CKE Community Centre (1015 73 Ave SW, Calgary, AB).

Everyone is welcome

If you are interested in attending via Zoom please sign up [HERE](#)

September 18 Guest Speaker Linda Vorster



“Updates on hearing health: what everyone needs to know”

Linda has worked in the hearing care industry since 2011, demonstrating a profound commitment to promoting awareness of hearing health and emphasizing the empowerment derived from knowledge.

Holding a bachelor's degree in Drama and a postgraduate diploma in Education and Hearing Aid Acoustics, Linda currently practices in Canada as a Registered Hearing Aid Practitioner at the esteemed and award-winning hearing clinic 'Audiology Innovations'. She is Audiology Innovation's training lead, working closely with Dr. Carrie Scarff to ensure the highest level of hearing care standards for the entire group of clinicians and clinics across Calgary and Red Deer. She also maintains board certification in Hearing Instrument Sciences. Her dedication lies in collaborating with patients to enhance their overall quality of life.

Overview of presentation:

This presentation covers hearing loss identification, brain health research updates AND the latest technology available to improve people's hearing in noise.

Upcoming Events

Warriors & Wives Partners and Caregivers

Please come and join us on Wednesday September 18th with our guest speaker Linda Vorster. We are meeting at CKE starting at 6:00 pm with a social gathering in the lounge and separate meetings from 6:30 to 7:30 prior to the general meeting in the main hall.

Exciting Opportunity Alert! Prostaïd Calgary is on the lookout for passionate individuals eager to make a real difference. Join us as a Board Member and play a vital role in our impactful mission. Your skills and dedication can help shape a brighter future. "If you believe this is the perfect opportunity for you, we'd love to hear from you!

Reach out to any of our Board members or connect with me directly at program.director@prostaïd.org.

SEPTEMBER IS PROSTATE CANCER AWARENESS MONTH

Hi everyone! As we enter this month of Prostate Cancer Awareness, we're looking for your story. Everyone that has or knows of someone who is dealing with Prostate Cancer, we would like to share their story on our website in hopes of bringing awareness as well as to encourage one another that you are not alone in this battle.

We are looking for a short paragraph or two from our members, warriors, wives and caregivers. Of course, you can be completely anonymous if you decide to be, or if you want to share your name, that's okay as well.

If this is of interest to you or if you have any questions or concerns, please email me at program.director@prostaïd.org



Donate Today

PROSTAID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over \$20.00.

Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.

Donate Today

Connect With Us

Information
Phone 403 455 1916
info@prostaid.org
Brad Sterling
President
president@prostaid.org

[Connect With Us](#)

Support Groups

Frank Altin
Warriors
faltin@telusplanet.net
Wives, Partners & Caregivers
Newly Diagnosed
info@prostaid.org

[Meeting Info Here](#)

Articles Of Interest



DRIVING CHANGE FOR MEN'S HEALTH

The MAN VAN® is Canada's first and only mobile men's health clinic offering FREE PSA (Prostate Specific Antigen) blood testing used for early detection of prostate cancer.

Now serving Edmonton & north for men 40 to 70 and for men between 40 and 49 please go to Get Checked for specific details.

- No appointment necessary
- Find the next community clinic near you
- 15 minutes can save your life!

[MAN VAN UPCOMING CLINICS](#)




Clinical Activity Seen in T-Cell Therapy for Solid Tumors

A total of 58 patients were evaluated for disease response and received three escalating doses of the CAR T-cell therapy. All of the patients achieved stable disease for at least 2 months following the clinical trial. Twenty-nine patients had partial responses and one had a complete response. In addition, a patient had a complete response after receiving additional CAR T-cell therapy cycles off protocol.

Trial Results

August 2024
Oncology Times

[T-Cell Therapy](#)




Olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a Phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites..

August 2024
MedicalXpress

Olaparib




Study suggests an MRI may help doctors predict more aggressive prostate cancer in patients

New Corewell Health research suggests an MRI scan can help predict whether patients with intermediate-risk prostate cancer (cancer confined to the entire prostate) may have more aggressive cancer in five years. Knowing this could potentially help doctors determine if treatment is needed up front vs. using a method called active surveillance where the disease is closely monitored over time.

Trial Results

August 2024
Medical Xpress

MRI



Study launches of MOMA-313 in solid tumors, including prostate cancer

The phase 1 trial is assessing the safety and tolerability of MOMA-313 as both a monotherapy and in combination with olaparib in patients with HR-deficient advanced or metastatic solid tumors.

Trial Info

August 2024
Urology Times

MOMA-313




Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis.

Prostate cancers often depend on the male sex hormone, testosterone, to grow. Androgen deprivation therapy (ADT) is used to lower testosterone levels in patients with advanced prostate cancer. ADT options available to patients have different characteristics, including how they are taken (injection or pill), side effects, impact on sexual interest, and costs.

Trial Results

August 2024
URO Today

ADT Therapies




Precision therapy for metastatic prostate cancer offers improved survival

Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than chemotherapy. However, the effect depends on which mutations the patient's tumor carries.

More information

August 2024
MedicalXpress

Precision therapy



Combining PI-RADS and PRIMARY scores improves prostate cancer detection

In the long-term, this will enable us to safely avoid the need for biopsy in a high proportion of patients. It will also allow us to change the type of biopsy required for those patients in whom the chance of clinically significant malignancy is 100%, or even skip the biopsy and go straight to prostatectomy.

[More info here](#)

August 2024
Urology Times

PI-RADS




Fig. 3 | ROC curves for ClarityDX Prostate, PHI, PBCG, % Free PSA, and PSA when predicting grade group ≥ 2 prostate cancer for Thomas University Hospital patients.

Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform

The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification of csPCa while avoiding unnecessary biopsies in men with non-csPCa is challenging. We built an optimized machine learning platform (ClarityDX) and showed its utility in generating models predicting csPCa.

ClarityDX

Read about these articles below

- 1-Suicide attempt, death up for spouses of patients with cancer
- 2-Living with prostate cancer
- 3-Managing Urinary Incontinence
- 4-Disadvantaged neighbourhoods may contribute to radical disparities in risk of aggressive prostate cancer'
- 5-New insights into biomarkers and probes for prostate cancer
- 6-A discussion on nutrition and prostate cancer
- 7-Simplifying the Management of Very Low-Risk Prostate Cancer
- 8-Men's Health, BPH, & Prostate Cancer
- 9- Canadian Prostate Cancer

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



For Caregivers & Families




Suicide attempt, death up for spouses of patients with cancer

Spouses of patients with cancer have an increased risk for suicide attempt and suicide death, especially during the first year after diagnosis, according to a study [published](#) online Aug. 15 in *JAMA Oncology*.

[More Info](#)

August 2024
Oncology & Cancer

Suicide




Living with prostate cancer. What will the impact be on my emotions and wellbeing?

Diagnosis and treatment of prostate cancer can lead to a shift in your sense of identity, which can be difficult to deal with. For example, you may be unable to work or experience physical changes that affect your body image. It can also be an isolating experience and you may feel that those around you don't understand..

Prostate Cancer Research

Wellbeing



Managing Urinary Incontinence What is urinary incontinence and how is it treated?

Urinary incontinence or leaking urine is a common side effect of prostate cancer treatment. Some treatments for prostate cancer, such as prostatectomy and radiotherapy, can cause damage to the nerves and muscles needed for peeing. Your individual risk of developing urinary incontinence will depend on your treatment and whether you have had problems with leaking urine before.

PCRI

Urinary Incontinence




Disadvantaged neighbourhoods may contribute to radical disparities in risk of aggressive prostate cancer

Our study findings suggest that neighborhood disadvantage adversely impacts stress-related genetic pathways in the body. We believe that this may in turn increase an individual's risk of aggressive prostate cancer,” study senior author Kathryn Hughes Barry, tells *Cancerworld*.

August 2024
Cancerworld

Disadvantaged



New insights into biomarkers and probes for prostate cancer

Prostate cancer is characterized by a multitude of molecular aberrations that complicate its early detection and treatment. The review discusses various biomarkers across molecular, cellular, and exosomal categories, showcasing their potential to revolutionize how prostate cancer is diagnosed and treated.

[More Info](#)

August 2024
Oncology & Cancer

Biomarkers

New Videos




A discussion on nutrition and prostate cancer with nutrition expert Verne Varona

Nutrition Questions

- 1- What's the best diet for prostate cancer?
- 2- What about red meat and animal protein?
- 3-How should vegetarians eat?
- 4- Are there "cancer fighting" foods?

August 2024
PCRI

Nutrition



Simplifying the Management of Very Low-Risk Prostate Cancer-Rashid Sayyid & Zachary Klaassen

Dr. Sayyid defines very low-risk prostate cancer using criteria like T1C stage, PSA levels, and biopsy characteristics. The updated guidelines simplify management based on life expectancy: patients with 10 years or more are recommended active surveillance, while those with less are advised observation.

June 2024
URO Today

Low-Risk Video



Men's Health, BPH, & Prostate Cancer Q&A With Mark Moyad & Mark Scholz

In this engaging Q&A video, Dr. Mark Scholz and Dr. Mark Moyad, leading experts in prostate health, team up to address your most pressing questions about men's health, Benign Prostatic Hyperplasia (BPH), and prostate cancer. Dr. Scholz, an oncologist specializing in prostate cancer, brings his wealth of experience in cutting-edge treatments and patient care.

July 2024
PCRI

Mens Health

Canadian Prostate Cancer Guide

Resources, guides and tools to help caregivers, survivors and the recently diagnosed get clarity and more. Read empowering stories and share yours with us.

Bringing you the most up to date information in treatments, support, well-being, and more all in one place

We can help you in achieving the support you're looking for. On the Canadian Prostate Cancer Guide website you can look to find the most up to date information on prostate cancer in one place.

[Learn More Here](#)

Thank you to our Sponsors and Community Partners



Disclaimer: The PROSTAID Calgary Society website & newsletter provides news and information about prostate issues and activities of the organization. While information is presented about prostate cancer and related issues, it is not intended as a substitute for professional medical advice, diagnosis, or treatment. PROSTAID Calgary Society recommends that you seek the advice of your physician or other qualified health professionals regarding questions you may have about any medical condition. Topics on PROSTAID Calgary Society's website & newsletter are presented to inform you and we encourage you to seek professional medical advice before starting any treatment.

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



[Unsubscribe](#)